Early Detection of Thalassemia: Screening and Diagnostic Tests

Thalassemia is one of the most common inherited blood disorders in the world, affecting an estimated 5-7% of the global population. Because it is a genetic condition passed from parents to children, its impact is felt not just by individuals but across generations and communities. The good news is that thalassemia can be detected early – sometimes even before a child is born – through a structured set of screening and diagnostic tools. Early detection is not just a medical step; it is a life-altering opportunity for families to plan, prepare, and make informed decisions.

Why early detection matters 🔗

Thalassemia follows an autosomal recessive inheritance pattern. This means both parents must carry a faulty gene for a child to be born with the severe form of the disease. Many carriers have no symptoms at all and are entirely unaware they carry the mutation. Without proactive screening, a new case of thalassemia major could occur with alarming frequency in high-prevalence regions. Early detection – whether before marriage, during pregnancy, or at birth – allows for timely medical management and, in many cases, the prevention of severe disease altogether.

Premarital and preconception screening 🔗

The earliest and most proactive point of intervention is before marriage or conception. Healthy carriers of beta-thalassemia can be identified inexpensively and accurately by a simple blood test, and couples who undergo testing can be informed about their genetic risks and given options. When both partners carry the thalassemia trait, there is a 25% chance with every pregnancy that the child will have thalassemia major.

Premarital screening programs have demonstrated measurable success in reducing the prevalence of the disease. In Sardinia, a long-term voluntary screening program reduced the birth rate of thalassemia major from 1 in 250 live births to 1 in 4,000 – a dramatic reduction attributed to education, carrier screening, and genetic counseling. Similarly, the National Thalassemia Prevention Programme in Northern Greece achieved a 90% reduction in affected newborns over a 15-year period. Premarital screening programs and prenatal diagnosis in Cyprus, Greece, and Italy have achieved 100% success, with the birth prevalence of homozygous beta-thalassemia reaching zero in those countries.

Countries like Iran, Saudi Arabia, and Bahrain have implemented mandatory or quasi-mandatory premarital screening programs with significant results. Saudi Arabia’s National Premarital Screening Program, launched in 2003, screened nearly 500,000 individuals in its first two years, identifying thousands of carriers and at-risk couples. The technical process for premarital screening typically begins with a Complete Blood Count (CBC) and hemoglobin electrophoresis, followed by DNA analysis when necessary.

Prenatal diagnosis: CVS and amniocentesis 🔗

When both partners are confirmed carriers, prenatal diagnosis is available to determine whether the fetus has inherited the condition. Two primary invasive procedures are used.

Chorionic Villus Sampling (CVS) 🔗

Invasive prenatal diagnosis can be performed from the first trimester by chorionic villus sampling (CVS). In this procedure, a small sample of placental tissue – derived from the same fertilized egg as the fetus – is collected using a catheter or needle. Prenatal diagnosis of thalassemia is preferably carried out by CVS in the first trimester, typically between 10 and 12 weeks of pregnancy. The DNA obtained from the placental sample is then analyzed to determine whether the fetus has inherited the disease-causing mutations from both parents. CVS offers the advantage of earlier diagnosis, allowing couples more time and options for decision-making.

Amniocentesis 🔗

Amniocentesis is not usually performed earlier than the 15th week of pregnancy, making it a second-trimester procedure. It involves withdrawing a small amount of amniotic fluid from around the fetus using a thin needle guided by ultrasound. The fluid contains fetal cells whose DNA can be analyzed for thalassemia mutations. A CVS is ideally performed between 10 to 13 weeks while amniocentesis is typically performed between 15 to 24 weeks. Both procedures carry a small risk of complications including miscarriage, so they are recommended specifically for couples identified as being at high risk through prior screening. Genetic counseling before and after these procedures is considered essential.

Newborn screening 🔗

Even when prenatal screening has not been conducted, thalassemia can still be detected at birth. Newborn screening programs use a simple heel-prick blood test, taken within the first few days of life, to collect a small blood sample for analysis. Newborn screening methodologies used to detect sickle cell disease also detect alpha-thalassemia, and most programs use high-performance liquid chromatography (HPLC) or isoelectric focusing (IEF) as primary screening techniques.

Initial newborn screening in most states uses HPLC or IEF on a spot of blood, which detect hemoglobin variants and provide data to support a thalassemia diagnosis. The advantage of newborn screening is that it enables early medical intervention before severe symptoms develop, significantly improving long-term outcomes. In cases where a result is positive, confirmatory testing using molecular methods is carried out.

Blood test: Complete Blood Count (CBC) 🔗

For individuals who have not undergone earlier screening, the Complete Blood Count (CBC) is typically the first diagnostic test ordered when thalassemia is suspected. The first step in the evaluation of a suspected thalassemia is a CBC with peripheral smear. This test measures key blood parameters including the number of red blood cells (RBCs), white blood cells (WBCs), platelets, hemoglobin concentration, and hematocrit.

In thalassemia, the CBC typically reveals a low Mean Corpuscular Volume (MCV) and low Mean Corpuscular Hemoglobin (MCH), indicating that the red blood cells are smaller and paler than normal – a condition called microcytic hypochromic anemia. While low MCV and MCH are characteristic of thalassemic red blood cells, these indices alone cannot distinguish between thalassemia trait and iron deficiency anemia, which is why further testing is always required. A peripheral blood smear can also reveal abnormal red cell shapes such as target cells and teardrop cells, providing additional diagnostic clues.

Clinical symptoms and confirmatory laboratory tests 🔗

In children who have not been identified through screening programs, clinical symptoms often prompt the diagnostic process. Common signs of moderate to severe thalassemia include pale skin, fatigue, poor growth, jaundice, abdominal distension due to an enlarged liver or spleen, and bone deformities from the expansion of bone marrow trying to compensate for inadequate red blood cell production. Most children with moderate to severe thalassemia show symptoms within their first two years of life.

Once clinical suspicion is established, confirmatory laboratory tests are essential. The most important of these is Haemoglobin Electrophoresis (or its more modern equivalent, High Performance Liquid Chromatography / HPLC). In addition to the CBC, hemoglobin electrophoresis is the first confirmatory diagnostic test, measuring fractions of hemoglobin A, A2, F, H, E, and other variants. In beta-thalassemia carriers, for instance, the level of HbA2 is typically elevated above 3.5%, while HbF may also be raised. These findings help distinguish between different types and severities of thalassemia and rule out other causes of anemia.

At least two complementary techniques – such as a combination of HPLC and electrophoresis – should be used in the initial identification of a thalassemia, since different hemoglobin variants can sometimes interfere with one another, leading to incorrect results if only a single method is used.

Genetic testing: DNA analysis 🔗

While hemoglobin analysis can strongly suggest a diagnosis, genetic testing – also called DNA analysis – is the definitive tool for confirming thalassemia, determining its type, and identifying the specific mutation involved. Conventional thalassemia diagnosis uses hematological and biochemical tests first, followed by DNA analysis for definitive diagnosis.

Genetic testing distinguishes between alpha-thalassemia (caused by deletions or mutations in the HBA1 and HBA2 genes) and beta-thalassemia (caused by mutations in the HBB gene). It also identifies whether the individual is a carrier (one faulty gene copy) or has the full disorder (two faulty gene copies), and it predicts disease severity. Common methods include PCR-based techniques such as Gap-PCR and ARMS-PCR for detecting known mutations, and Sanger sequencing for rarer or unidentified mutations. More recently, Next-Generation Sequencing (NGS) has been introduced for thalassemia screening, and preliminary data show it may be significantly more accurate than conventional CBC and hemoglobin analysis methods.

Genetic testing is also the backbone of carrier screening programs. Prenatal detection of thalassemia is possible through non-invasive prenatal testing (NIPT), a simple blood test that analyzes cell-free fetal DNA in maternal blood. While NIPT is not yet fully diagnostic on its own, it represents a promising advance that reduces reliance on invasive procedures for initial risk assessment.

A stepwise approach to detection 🔗

In practice, the detection of thalassemia follows a clear stepwise pathway. The diagnosis of thalassemias relies on a stepwise approach, beginning with clinical suspicion and routine blood tests and moving toward confirmatory studies such as hemoglobin electrophoresis or genetic testing. Premarital and prenatal screening catches cases before birth; newborn screening identifies affected infants immediately after delivery; and clinical evaluation with CBC, hemoglobin analysis, and DNA testing confirms the diagnosis at any stage of life. Each level of this system plays a role in reducing the burden of thalassemia – both on individuals and on healthcare systems.

The data from countries that have invested in comprehensive screening programs is compelling. When communities have access to accurate testing, genetic counseling, and reproductive choices, the incidence of severe thalassemia can be dramatically reduced – and in some cases, eliminated as a major public health concern.

What do you think? If premarital thalassemia screening were made mandatory in high-prevalence regions, how should healthcare systems balance public health benefits with individual privacy and personal choice? And considering how far detection technology has advanced – from basic blood tests to next-generation DNA sequencing – what would it take to make these diagnostic tools accessible to families in low-resource settings?

References

1. https://arupconsult.com/content/thalassemias
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3915444/
3. https://journals.sagepub.com/doi/10.1258/jms.2008.008029
4. https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03344-1
5. https://www.nature.com/articles/gim200760
6. https://www.sciencedirect.com/science/article/abs/pii/S1521693416301195
7. https://www.intechopen.com/chapters/60442
8. https://unityscreen.com/conditions/beta-thalassemia
9. https://www.cdc.gov/mmwr/volumes/69/wr/mm6936a7.htm
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC8791174/
11. https://www.thebloodproject.com/diagnosis-of-thalassemia/
12. https://www.mayoclinic.org/diseases-conditions/thalassemia/diagnosis-treatment/drc-20355001
13. https://thalassemia.ucsf.edu/thalassemia-information/symptoms-diagnosis
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7326097/
15. https://medicover-genetics.com/genetic-testing-of-thalassemia-carrier-screening-and-nipt/